Table 3.
Hazard ratio of PSA recurrence-free survival of established prognostic parameters and BCAR1 expression
| Scenario | 1 | 2 | 3 | 4 | |
|---|---|---|---|---|---|
| Analyzable (N) | 8522 | 8662 | 8778 | 5362 | |
| Preoperative | Gleason score biopsy | ||||
| 3 + 4 vs. ≤3 + 3 | 1.98 *** | ||||
| 4 + 3 vs. 3 + 4 | 1.62 *** | ||||
| ≥ 4 + 4 vs. 4 + 3 | 1.30 *** | ||||
| Clinical tumor (cT) stage | |||||
| T2a vs. T1c | 1.33 *** | 1.33 *** | |||
| T2b vs. T2a | 1.47 *** | 1.40 *** | |||
| T3a vs. T2c | 0.62 * | 0.65 * | |||
| Preoperative PSA level | |||||
| 4–10 vs. <4 | 1.45 *** | 1.38 ** | 1.21 * | 1.17 | |
| 10–20 vs. 4–10 | 1.52 *** | 1.43 *** | 1.28 *** | 1.19 * | |
| > 20 vs. 10–20 | 1.69 *** | 1.53 *** | 1.20 * | 1.19 * | |
| BCAR1 expression | |||||
| Weak vs. negative | 1.17 * | 1.14 | 1.16 * | 1.29 * | |
| Moderate vs. weak | 0.91 | 0.92 | 0.88 | 0.78 * | |
| Strong vs. moderate | 1.14 * | 1.08 | 1.12 | 1.13 | |
| Postoperative | Gleason score prostatectomy | ||||
| 3 + 4 vs. ≤3 + 3 | 3.05 *** | 2.48 *** | 2.24 *** | ||
| 4 + 3 vs. 3 + 4 | 2.56 *** | 2.13 *** | 2.01 *** | ||
| ≥ 4 + 4 vs. 4 + 3 | 1.70 *** | 1.20 * | 1.11 | ||
| Pathological tumor (pT) stage | |||||
| T3a vs. T2 | 2.00 *** | 2.03 *** | |||
| T3b vs. T3a | 1.72 *** | 1.55 *** | |||
| T4 vs. T3b | 1.38 * | 1.35 | |||
| Surgical margin (R) status | |||||
| R1 vs. R0 | 1.44 *** | 1.31 *** | |||
| Lymph node (N) status | |||||
| N+ vs. N0 | 1.44 *** | ||||
Scenario 1 combines preoperatively available parameter (preoperative Gleason score obtained on the original biopsy, clinical tumor (cT) stage, and preoperative PSA) with the postoperative BCAR1 expression. In scenario 2 the biopsy Gleason is replaced by the Gleason score obtained on radical prostatectomy (RPE). In scenario 3 cT-stage is superseded by pathological tumor (pT) stage and surgical margin (R) status. In scenario 4 the lymph node (pN) stage is added. Asterisk indicate significance level: * p ≤ 0.05, ** p ≤ 0.001, and *** p ≤ 0.0001